Medical Device

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, is pleased to announce that Dr. Sarah Butler has been appointed Vice President, Clinical and Medical Affairs, effective immediately.

Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are thrilled to welcome Dr. Sarah Butler to our team whose expertise in medical affairs and clinical strategy will be a great asset for Perimeter. As we approach launching our pivotal study for clinical validation of our ImgAssist AI software and look towards what is next for our exciting technology, Sarah will provide executive leadership of the development and execution of clinical strategies that establish and expand upon our value proposition with our customers."

Dr. Sarah Butler stated, "I am excited to be joining Perimeter as the company embarks upon important clinical development initiatives supporting its OCT technology platform, which has the potential to address clear unmet medical needs in surgical specimen imaging. I look forward to contributing to the advancement of Perimeter's clinical programs with the goal of bringing this innovative technology to physicians and surgeons, who are striving to improve patient outcomes and lower healthcare costs."

Dr. Sarah Butler brings to Perimeter extensive healthcare industry experience and a reputation as an expert in global medical education and scientific communication, healthcare systems, clinical trial strategy, conduct, and compliance in clinical and industry environments. Most recently, Dr. Butler was a RAQA (Regulatory Affairs/Quality Assurance) Executive for IBM Watson Health, where she led the development of clinical strategic programs and products in the Watson Health Imaging Division. Previously, since 2013, Dr. Butler has provided leadership and medical expertise guiding the development of clinical strategic programs and products in the fields of infectious disease, oncology, companion diagnostics, medical genetics, and clinical genetics testing at companies including Abbott Inc. and Illumina, Inc. From May 2009 to September 2013, Dr. Butler was Director of the Clinical Cytogenetics Diagnostic Laboratory at Cincinnati Children's Hospital Medical Center and Assistant Professor of Pediatrics at the University of Cincinnati College of Medicine. Dr. Butler has a Bachelor of Science in Biology-Genetics from Heidelberg College and a PhD in Biomedical Biology-Molecular Genetics and Molecular Physiology from the University of Dayton. Dr. Butler was a Clinical Post-doctoral Cytogenetics Fellow at Cincinnati Children's Hospital Medical Center.

About Perimeter S-Series OCT

Cleared by the U.S. FDA, Perimeter S-Series Optical Coherence Tomography (OCT) is a novel medical imaging system that provides clinicians with cross-sectional, real-time margin visualization (1-2 mm below the surface) of an excised tissue specimen. Giving physicians the ability to visualize microscopic tissue structures "real time" in the operating room has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system.

About Perimeter B-Series OCT with ImgAssist AI

Perimeter is advancing the development of its proprietary, next-gen "ImgAssist" artificial intelligence technology under its ATLAS AI project, which is made possible, in part, by a US$7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT). The U.S. FDA granted Breakthrough Device Designation for Perimeter B-Series OCT coupled with ImgAssist AI, and Perimeter has plans to initiate a randomized, multi-site, pivotal study to evaluate it against the current standard of care and assess the impact on re-operation rates for patients undergoing breast conservation surgery.

About Perimeter Medical Imaging AI, Inc.

With headquarters in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month, underscoring the company's dedication to helping surgeons, radiologists, and pathologists use Perimeter's imaging technology and AI in the fight against breast cancer, which is estimated to account for 30% of all female cancer diagnoses this year.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that may constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results, and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, Perimeter's plans to initiate a pivotal study of its B-Series OCT is forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's most recent Management Discussion and Analysis which is available on Perimeter's SEDAR profile at www.sedar.com , and could cause actual events or results to differ materially from those projected in any forward-looking statements. In particular, we note the risk that our technology may not achieve the anticipated benefits in terms of surgical outcomes. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

Shushu Feng
Perimeter Medical Imaging AI, Inc.
(647) 360-0302
media@perimetermed.com

Ben Shamsian or Joe Dorame
Lytham Partners, LLC
Direct: 646-829-9701
Main: 602 889 9700
PINK@lythampartners.com

News Provided by Business Wire via QuoteMedia

Alkaline Fuel Cell Power Advances $2.2 Million CHP Capital Project for Toronto Condo Featuring 25 Years of Expected Revenue Generation

Alkaline Fuel Cell Power Advances $2.2 Million CHP Capital Project for Toronto Condo Featuring 25 Years of Expected Revenue Generation

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that PWWR Flow, the combined heat and power ("CHP") brand of the Company, is advancing a CHP project of approximately $2.2 million in capital for a condominium in mid-town Toronto, Canada (the " CHP Project "). The CHP Project is expected to generate more than $16 million in total revenue for PWWR Flow over a 25-year Energy Service Agreement ( "ESA ") timeframe.

"Our PWWR Flow brand is positioned to deliver more immediate revenue and contribute to earnings for AFCP as a complement to our longer-term, hydrogen-powered alkaline fuel cells ", commented Frank Carnevale, CEO. "We are actively moving through our $50 million sales pipeline of CHP projects, and we have already begun discussions to grow beyond it."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
CoinSmart Announces Q2 2022 Financial Results

CoinSmart Announces Q2 2022 Financial Results

/NOT FOR DISTRIBUTION IN THE US/

CoinSmart Financial Inc. ("CoinSmart" or "CFI") (NEO: SMRT) (FSE: IIR), a leading Canadian headquartered crypto asset trading platform, announces the release of its condensed interim consolidated financial statements for the three months ended June 30, 2022 and related management discussion and analysis. These documents will be posted on CoinSmart's website at www.coinsmart.cominvest and SEDAR at www.sedar.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Applied UV Reports Revenue of $5.9 Million for Second Quarter 2022

Applied UV Reports Revenue of $5.9 Million for Second Quarter 2022

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced its financial results for the second quarter 2022.

Recent Business Highlights

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
GMG to Acquire THERMAL-XR Manufacturing Intellectual Property and Brand Rights to Set Stage for Global Growth

GMG to Acquire THERMAL-XR Manufacturing Intellectual Property and Brand Rights to Set Stage for Global Growth

Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG") is pleased to announce that GMG and OzKem Pty Ltd ("OzKem") have signed a binding agreement for GMG to acquire the manufacturing intellectual property and brand rights of OzKem's THERMAL-XR® coating products. OzKem developed the THERMAL-XR® coating system products using GMG graphene together with OzKem's base HVAC (Heating Venting and Air Conditioning) coating. GMG is an international distributor of THERMAL-XR® products with a number of global commercial demonstrations underway or initial sales completed. Following the completion of the agreement GMG will own the THERMAL-XR® brand, will buy the base coatings product from OzKem, and GMG will manufacture the THERMAL-XR® products containing GMG graphene.

Under a binding detailed agreement, GMG and OzKem have agreed to the following terms:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Alkaline Fuel Announces Increase in Assets and Revenues in Filing of Second Quarter 2022 Financial Statements and MD&A

Alkaline Fuel Announces Increase in Assets and Revenues in Filing of Second Quarter 2022 Financial Statements and MD&A

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce today that the Company has filed its financial and operating results for the three and six month periods ended June 30, 2022. Select financial and operational information is outlined below and should be read in concert with AFCP's consolidated financial statements and management's discussion and analysis ("MD&A") for the second quarter and first half 2022, available on SEDAR at www.sedar.com and on AFCP's website at www.fuelcellpower.com .

"AFCP is diversifying its investments into more immediate revenue generating investments such as its CHP assets, and improving its ability to bring its fuel cells to market, quicker," commented Frank Carnevale, Chief Executive Officer. "Investors want a more de-risked investment platform, and we're on our way to delivering."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Applied UV to Host Second Quarter 2022 Conference Call on August 16, 2022

Applied UV to Host Second Quarter 2022 Conference Call on August 16, 2022

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will be hosting an investor conference call and live webcast on Tuesday, August 16, 2022 at 9:00 am ET to review its financial results. Second quarter 2022 financial results will be released after market close on Monday, August 15 th and will be available through the Investor Relations section of the company's website at https://irdirect.net/AUVI .

Conference Call/Webcast Information

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×